EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome

EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome

BackgroundLeptomeningeal metastases (LM) have become increasingly common in non-small cell lung cancer (NSCLC) patients who harbor epidermal growth factor receptor (EGFR) mutation treated with EGFR-TKI and are correlated with inferior prognosis. Evidence in prior research demonstrated that EGFR ampl...

Full description

Bibliographic Details
Main Authors: Hainan Yang, Lei Wen, Chao Zhao, Xuefei Li, Changguo Shan, Da Liu, Weiping Hong, Zhaoming Zhou, Cheng Zhou, Linbo Cai, Caicun Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
cerebrospinal fluid
leptomeningeal metastases
EGFR gene amplification
EGFR-TKI
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.902664/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.902664/full

Similar Items